LEADER 01683nam  2200421 a 450 
001 9910700723503321
005 20111011141730.0
035   $a(CKB)5470000002411775
035   $a(OCoLC)741958525
035   $a(EXLCZ)995470000002411775
100   $a20110721d2011      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aStaff report on Sanofi's strategic use of third parties to influence the FDA$b[electronic resource] /$fprepared by the staff of the Committee on Finance, United States Senate
210  1$aWashington :$cU.S. G.P.O.,$d2011.
215   $a1 online resource (iii, 177 pages)
225 1 $aS. prt. ;$v112-20
300   $aTitle from title screen (viewed on July 21, 2011).
300   $aAt head of title: 112th Congress, 1st session. Committee print.
300   $aPaper version available for sale by the Supt. of Docs., U.S. G.P.O.
300   $a"May 2011."
320   $aIncludes bibliographical references.
606   $aDrug approval$xCorrupt practices$zUnited States
606   $aAnticoagulants (Medicine)$xGovernment policy$zUnited States
606   $aGeneric drugs$xGovernment policy$zUnited States
615  0$aDrug approval$xCorrupt practices
615  0$aAnticoagulants (Medicine)$xGovernment policy
615  0$aGeneric drugs$xGovernment policy
712 02$aUnited States.$bCongress.$bSenate.$bCommittee on Finance.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910700723503321
996   $aStaff report on Sanofi's strategic use of third parties to influence the FDA$93197227
997   $aUNINA